The most news-worthy takeaway is obviously that the panel vote overwhelmingly against recommending the booster, something I think most people would have expected. Approving it for a small, high-risk subsegment of the population isn't particularly newsworthy.
The most newsworthy part is that it was approved for some, and that is in the headline.